The effect of curcumin on symptoms and quality of life in patients with irritable bowel syndrome

[1] Bartnik W, Chojnacki J, Paradowski L, Skrzydło-Radomańska B, Tomeski R. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterol Klin. 2009; 1: 9–17. BartnikW ChojnackiJ ParadowskiL Skrzydło-RadomańskaB TomeskiR Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego Gastroenterol Klin 2009 1 9 17 Search in Google Scholar

[2] Pietrzak A, Skrzydło-Radomanska B, Mulak A, Lipiński M, Małecka-Panas E, Rydzewska G. Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego. Gastroenterology Rev. 2018; 13: 167–196. PietrzakA Skrzydło-RadomanskaB MulakA LipińskiM Małecka-PanasE RydzewskaG Rekomendacje diagnostyczno-terapeutyczne w zespole jelita nadwrażliwego Gastroenterology Rev 2018 13 167 196 Search in Google Scholar

[3] Gwee K, Ghoshal U, Chen M. Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology and management. J Gastroenterol Hepatol. 2018; 33: 99–110. GweeK GhoshalU ChenM Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology and management J Gastroenterol Hepatol 2018 33 99 110 10.1111/jgh.1398728901578 Search in Google Scholar

[4] Drossman D. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016; 150: 1262–1279. DrossmanD Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV Gastroenterology 2016 150 1262 1279 10.1053/j.gastro.2016.02.03227144617 Search in Google Scholar

[5] Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000; 119: 654–660. GralnekIM HaysRD KilbourneA NaliboffB MayerEA The impact of irritable bowel syndrome on health-related quality of life Gastroenterology 2000 119 654 660 10.1053/gast.2000.1648410982758 Search in Google Scholar

[6] Cash BD, Epstein MS, Shah SM. A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms. Dig Dis Sci. 2006; 61: 560–571. CashBD EpsteinMS ShahSM A novel delivery system of peppermint oil is an effective therapy for irritable bowel syndrome symptoms Dig Dis Sci 2006 61 560 571 10.1007/s10620-015-3858-7472979826319955 Search in Google Scholar

[7] Ottillinger B, Storr M, Malfertheiner P, Allescher HD. STW 5 (Iberogast^®): A safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschur. 2013; 163: 65–72. OttillingerB StorrM MalfertheinerP AllescherHD STW 5 (Iberogast^®): A safe and effective standard in the treatment of functional gastrointestinal disorders Wien Med Wochenschur 2013 163 65 72 10.1007/s10354-012-0169-x358013523263639 Search in Google Scholar

[8] Bandy R, Walker AF, Middleton RW. Turmeric extract may improve irritable bowel syndrome symptomatology in otherwise healthy adults: a pilot study. J Alternative Complementary Med. 2004; 10: 1015–1018. BandyR WalkerAF MiddletonRW Turmeric extract may improve irritable bowel syndrome symptomatology in otherwise healthy adults: a pilot study J Alternative Complementary Med 2004 10 1015 1018 10.1089/acm.2004.10.101515673996 Search in Google Scholar

[9] Ng QX, Soh AYS, Loke W, Venkatanarayanan N, Lim DY, Yeo WS. A meta-analysis of the clinical use of curcumin for irritable bowel syndrome. J Clin Med. 2018; 7: 298–306. NgQX SohAYS LokeW VenkatanarayananN LimDY YeoWS A meta-analysis of the clinical use of curcumin for irritable bowel syndrome J Clin Med 2018 7 298 306 10.3390/jcm7100298621014930248988 Search in Google Scholar

[10] Portincasa P, Bonfrate L, Scribano ML, Kohn A, Caporaso N, Festi D, Campanale MC, Di Rienzo T, Guarino M, Taddia M, et al. Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome. J Gastrointestin Liver Dis. 2016; 25: 151–157. PortincasaP BonfrateL ScribanoML KohnA CaporasoN FestiD CampanaleMC Di RienzoT GuarinoM TaddiaM Curcumin and fennel essential oil improve symptoms and quality of life in patients with irritable bowel syndrome J Gastrointestin Liver Dis 2016 25 151 157 10.15403/jgld.2014.1121.252.ccm27308645 Search in Google Scholar

[11] Kunnumakkara AB, Bordoloi D, Harsha C, Banik K, Gupta SC, Aggarwal BB. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clin Sci. 2017; 131: 1781–1799. KunnumakkaraAB BordoloiD HarshaC BanikK GuptaSC AggarwalBB Curcumin mediates anticancer effects by modulating multiple cell signaling pathways Clin Sci 2017 131 1781 1799 10.1042/CS2016093528679846 Search in Google Scholar

[12] Tomeh MA, Hadianamrei R, Zhao X. A Review of curcumin and its derivatives as anticancer agents. Int J Mol Sci. 2019; 20: 1033. TomehMA HadianamreiR ZhaoX A Review of curcumin and its derivatives as anticancer agents Int J Mol Sci 2019 20 1033 10.3390/ijms20051033642928730818786 Search in Google Scholar

[13] Jiang MC, Yang-Yen HF, Yen JJ, Lin JK. Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer. 1996; 26: 111–120. JiangMC Yang-YenHF YenJJ LinJK Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines Nutr Cancer 1996 26 111 120 10.1080/016355896095144688844727 Search in Google Scholar

[14] Sikora-Polaczek M, Bielak-Żmijewska A, Sikora E. Molekularne i komórkowe mechanizmy działania kurkuminy – dobroczynny wpływ na organizm, Postępy Biochemii. 2011; 57: 74–84. Sikora-PolaczekM Bielak-ŻmijewskaA SikoraE Molekularne i komórkowe mechanizmy działania kurkuminy – dobroczynny wpływ na organizm Postępy Biochemii 2011 57 74 84 Search in Google Scholar

[15] Singh AK, Sidhu GS, Deepa T. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett. 1996; 107: 109–115. SinghAK SidhuGS DeepaT Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell Cancer Lett 1996 107 109 115 10.1016/0304-3835(96)04357-18913274 Search in Google Scholar

[16] Xu YX, Pindolia KR, Janakiraman N, Noth CJ, Chapman RA, Gautam SC. Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells. Exp Hematol. 1997; 25: 413–422. XuYX PindoliaKR JanakiramanN NothCJ ChapmanRA GautamSC Curcumin, a compound with anti-inflammatory and anti-oxidant properties, down-regulates chemokine expression in bone marrow stromal cells Exp Hematol 1997 25 413 422 Search in Google Scholar

[17] Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997; 11: 395–402. FrancisCY MorrisJ WhorwellPJ The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress Aliment Pharmacol Ther 1997 11 395 402 10.1046/j.1365-2036.1997.142318000.x9146781 Search in Google Scholar

[18] Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. Foods. 2017; 6: 92. HewlingsSJ KalmanDS Curcumin: A review of its effects on human health Foods 2017 6 92 10.3390/foods6100092566403129065496 Search in Google Scholar

[19] Derosa G, Maffioli P, Simental-Mendía LE, Derosa G, Maffioli P, Simental-Mendía LE. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016; 111: 394–404. DerosaG MaffioliP Simental-MendíaLE DerosaG MaffioliP Simental-MendíaLE Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials Pharmacol Res 2016 111 394 404 10.1016/j.phrs.2016.07.00427392742 Search in Google Scholar

[20] Xu Y, Ku B, Tie L, Yao H, Jiang W, Ma X, Li X. Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB. Brain Res. 2006; 1122: 56–64. XuY KuB TieL YaoH JiangW MaX LiX Curcumin reverses the effects of chronic stress on behavior, the HPA axis, BDNF expression and phosphorylation of CREB Brain Res 2006 1122 56 64 10.1016/j.brainres.2006.09.00917022948 Search in Google Scholar

[21] Wang J, Ghosh SS, Ghosh S. Curcumin improves intestinal barrier function: Modulation of intracellular signaling, and organization of tight junctions. Am J Physiol Cell Physiol. 2017; 312: C438–C445. WangJ GhoshSS GhoshS Curcumin improves intestinal barrier function: Modulation of intracellular signaling, and organization of tight junctions Am J Physiol Cell Physiol 2017 312 C438 C445 10.1152/ajpcell.00235.2016540701528249988 Search in Google Scholar

[22] Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4: 1502–1506. HanaiH IidaT TakeuchiK WatanabeF MaruyamaY AndohA TsujikawaT FujiyamaY MitsuyamaK SataM Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial Clin Gastroenterol Hepatol 2006 4 1502 1506 10.1016/j.cgh.2006.08.00817101300 Search in Google Scholar

[23] Kumar S, Ahuja V, Sankar MJ, Kumar A, Moss AC. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database of Syst Rev. 2012; 10: CD008424. KumarS AhujaV SankarMJ KumarA MossAC Curcumin for maintenance of remission in ulcerative colitis Cochrane Database of Syst Rev 2012 10 CD008424 10.1002/14651858.CD008424 Search in Google Scholar

[24] Selvam C, Prabu SL, Jordan BC, Purushothaman Y, Umamaheswari A, Hosseini Zare MS, Thilagavathi R. Molecular mechanisms of curcumin and its analogs in colon cancer prevention and treatment. Life Sci. 2019; 15: 117032. SelvamC PrabuSL JordanBC PurushothamanY UmamaheswariA Hosseini ZareMS ThilagavathiR Molecular mechanisms of curcumin and its analogs in colon cancer prevention and treatment Life Sci 2019 15 117032 10.1016/j.lfs.2019.11703231704450 Search in Google Scholar

[25] Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21: 2895–2900. ChengAL HsuCH LinJK HsuMM HoYF ShenTS KoJY LinJT LinBR Ming-ShiangW Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions Anticancer Res 2001 21 2895 2900 Search in Google Scholar

[26] Błasiak J, Trzeciak A, Małecka-Panas E, Drzewoski J, Iwanienko T, Szumiel I, Wojewódzka M. DNA damage and repair in human lymphocytes and gastric mucosa cells exposed to chromium and curcumin. Teratog Carcinog Mutagen. 1999; 19: 19–31. BłasiakJ TrzeciakA Małecka-PanasE DrzewoskiJ IwanienkoT SzumielI WojewódzkaM DNA damage and repair in human lymphocytes and gastric mucosa cells exposed to chromium and curcumin Teratog Carcinog Mutagen 1999 19 19 31 10.1002/(SICI)1520-6866(1999)19:1<19::AID-TCM3>3.0.CO;2-H Search in Google Scholar

[27] Wang Y, Yu J, Cui R, Lin J, Ding X. Curcumin in treating breast cancer: A review. J Lab Autom. 2016; 21: 723–731. WangY YuJ CuiR LinJ DingX Curcumin in treating breast cancer: A review J Lab Autom 2016 21 723 731 10.1177/2211068216655524 Search in Google Scholar

[28] Hou X, Chen S, Zhang Y, Sha W, Yu X, Elsawah H, Afifi AF, El-Khayat HR, Nouh A, Hassan MF, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014; 34: 783–793. HouX ChenS ZhangY ShaW YuX ElsawahH AfifiAF El-KhayatHR NouhA HassanMF Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: Results of an international prospective observational cohort study in Poland, Egypt, Mexico and China Clin Drug Investig 2014 34 783 793 10.1007/s40261-014-0233-y Search in Google Scholar

[29] Ballou S, Beath S, Kaptchuk TJ, Hirsch W, Sommers T, Nee J, Iturrino J, Rangan V, Singh P, Jones M, Lembo A. Factors associated with response to placebo in patients with irritable bowel syndrome and constipation. Clin Gastroenterol Hepatol. 2018; 16: 1738–1744. BallouS BeathS KaptchukTJ HirschW SommersT NeeJ IturrinoJ RanganV SinghP JonesM LemboA Factors associated with response to placebo in patients with irritable bowel syndrome and constipation Clin Gastroenterol Hepatol 2018 16 1738 1744 10.1016/j.cgh.2018.04.009 Search in Google Scholar

[30] Bai T, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L, Wang H, Song J, Hou X. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey. J Gastroenterol Hepatol. 2017; 32: 1018–1025. BaiT XiaJ JiangY CaoH ZhaoY ZhangL WangH SongJ HouX Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross-sectional survey J Gastroenterol Hepatol 2017 32 1018 1025 10.1111/jgh.13642 Search in Google Scholar